To evaluate the diagnostic performance of fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for the preoperative assessment of lymph node metastases (LNM) in endometrial cancer patients and for the assessment of endometrial cancer recurrence (ECR) after primary surgical treatment.
or metabolic tumor characteristics may remain undetected. However, vigorous debate has challenged the use of anatomic assessments solely relying on tumor morphological information, not taking into account functional tumor characteristics that may prove highly relevant for the clinical phenotype (11) (12) (13) . In this regard, to better understand the tumor microenvironment, metabolic positron emission tomography (PET) tracers such as fluorodeoxyglucose (FDG), in combination with CT can overcome the limitations of morphological imaging alone, since functional changes possible to detect by FDG-PET/CT often precede morphological changes detectable by conventional MRI or CT (14, 15) .
FDG-PET/CT has long been used successfully for evaluation of several malignancies including endometrial cancer (15, 16) (Fig.1 ). Based on a systematic review, we here report diagnostic indices of FDG-PET/CT for preoperative prediction of lymph node metastases and for detection of disease recurrence after surgery with curative intent in endometrial cancer patients.
MATERIALS AND METHODS

Search Strategy
Because the study was not conducted on patients, no informed consent or ethical committee approval was needed. To identify all relevant publications we performed systematic searches in the bibliographic databases PUBMED.com from inception to August 17, 2015 . Search terms included controlled terms from Mesh in PUBMED.com using the following search terms 'FDG PET' in combination with 'Endometrial neoplasms'. The references of the identified articles were also searched for relevant publications.
Selection Process
One physician (VRB) and one statistician (OBB) reviewed each published article independently to determine the eligibility for inclusion in the meta-analysis, and to extract information regarding clinical patient data and PET/CT characteristics. From the studies selected, data on first author, year of publication, number of patients included, study design (prospective or retrospective), patient age (mean/median), results from surgical International Federation of Gynecology and Obstetrics (FIGO) staging, percentage with nodal metastases, percentage with endometrioid subtype, FDG-PET/CT technical characteristics and numbers for diagnostic performance of FDG-PET/CT (i.e. true negatives, false negatives, true positives, false positives, positive predictive value and negative predictive value) were extracted and recorded. Any differences were resolved by consensus.
PET/CT studies that met the following criteria were included. First, studies which reported the diagnostic performance of FDG-PET/CT in detecting lymph node metastases preoperatively and/or disease recurrence in endometrial cancer patients after primary surgery. Secondly, clinical studies which included at least 10 patients. Third, studies which applied FDG as a tracer on dedicated device and published after peer review. Studies on animals or in vitro studies, studies not available in full text or not written in English and non-original articles (e.g. reviews, editorials, letters, legal cases, interviews, case reports) were not evaluated systematically in this review.
Statistical Analysis
We performed standard methods recommended for meta-analysis of diagnostic test evaluations (17) . Statistical analyses were carried out using Meta-Disc 1.4 software (18). We computed pooled measures for the following test indices of each study: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR). Further the summary receiver operating characteristics curve (SROC) was constructed and the area under the SROC curve (AUC) was determined.
A random effects model was used for statistical pooling of the data. Pooled data were presented with 95% confidence intervals (CI). The CI for diagnostic indices are exact, i.e they are based on the binomial distribution and hence are asymmetric. The I-square index was used to test for heterogeneity between studies. The AUC was calculated to measure the overall diagnostic performance of FDG-PET/CT in detecting the LNM and endometrial cancer recurrence. The sensitivity and specificity for the single test threshold identified for each study were used to plot the SROC curve along with Q* index representing an overall measure of the test's discriminatory power.
RESULTS
Literature Search Results
The literature search yielded a total of 58 references in PUBMED.com. In addition, three relevant recent articles on LNM in endometrial cancer and one in ECR that we were aware of, were included in our database. The flow chart of the search and selection process is presented in Fig 2. Out of a total of 62 articles, only 21 were eligible according to the criteria. Tables 1 and 2 summarize details for the included endometrial cancer studies of LNM and ECR by FDG-PET/CT imaging, respectively.
Preoperative Detection of Lymph Node Metastases
In our meta-analysis of LNM, 13 studies were included, comprising a total of 861 endometrial cancer patients. The overall pooled diagnostic indices of preoperative FDG-PET/CT for detecting LNM are calculated on the patient basis. The pooled sensitivity and specificity values are 0.72 (95% CI: 0.63 to 0.80) (Fig. 3A) and 0.94 (95% CI: 0.93 to 0.96) (Fig. 3B) , respectively. The pooled PLR is 10.9 (95% CI: 7.9 to 15.1), the pooled NLR is 0.36 (95% CI: 0.27 to 0.48), and the DOR is 39.7 (95% CI: 21.4 to 73.6).
The SROC representing a global summary score for the test performance yielded an AUC of 0.94 and a Q* value of 0.88 (Fig. 3C ), indicating a relatively high level of overall accuracy.
Detection of Endometrial Cancer Recurrence
In the present meta-analysis for ECR, 8 studies comprising 378 patients have been included. The pooled sensitivity is 0.95 (95% CI: 0.91 to 0.98) (Fig. 4A) , while the pooled specificity is 0.91 (95% CI: 0.86 to 0.94) ( (Fig. 4C) , respectively, suggesting that the level of overall accuracy is high.
DISCUSSION
Lymphadenectomy is currently commonly applied for lymph node staging in endometrial carcinoma as part of the surgical FIGO staging systems. However, non-invasive accurate lymph node staging in endometrial cancer by preoperative imaging seems advantageous compared to the more invasive nature of surgical lymph node staging, also with an unproven survival benefit from the procedure (9,10). Similar to other tumors, endometrial cancer has an increased tumor glucose metabolism and glycolysis rate which makes it suitable for FDG-PET/CT imaging (19-21). The present meta-analysis yields very high diagnostic performances of FDG-PET/CT for diagnosing LNM preoperatively-High diagnostic accuracy was also demonstrated for the procedure detecting endometrial cancer recurrence after primary surgical treatment. This clearly supports a role of FDG-PET/CT to enable more accurately tailored primary surgical endometrial cancer treatment and subsequent patient care.
The pooled sensitivity for preoperative detection of lymph node metastases by FDG-PET/CT in this meta-analysis was 72%, highlighting that as much as about 1/4 of the metastatic lymph nodes are still missed by FDG-PET/CT. One possible explanation for this finding is that FDG avidity relies on the presence of sufficient number of malignant cells exhibiting increased glucose metabolism. Furthermore, the spatial resolution of PET/CT is not good enough to reliably detect small tumors or micro metastatic disease. There is no documented threshold for lymph node size allowing PET/CT to correctly identify metastatic lymph nodes in endometrial cancer, although one study, reported node based sensitivities of 17% (4/24) for nodes ≤4 mm, 67% (14/24) for nodes measuring 5-9 mm, and 93% (14/15) for nodes ≥ 10 mm (22). Similar figures with nodebased sensitivities of 13%, 67% and 100% in metastatic lymph nodes of ≤4 mm, 5-9 mm and ≥10 mm, respectively, in endometrial cancer was reported in another study (23). It should, however, be kept in mind, that although this meta-analysis found the overall sensitivity of FDG-PET/CT to be moderate for the detection of LNM in endometrial cancer, it compares favourably with the reported sensitivities for LNM detection by conventional MRI and CT (24).
A very high pooled specificity of 0.94 for metastatic lymph node detection by FDG-PET/CT was found in this study, and it may be argued that this specificity is sufficiently high to safely omit a major surgical procedure in patients with low risk based on results from preoperative endometrial biopsy and preoperative imaging, reducing operative and post-surgical complications and costs The findings in this study regarding FDG-PET/CT and ECR must, however, be interpreted with care, considering that the studies report lack of histological confirmation of all putative metastases based on FDG-PET/CT, and they report variable follow-up of the cases considered non-metastatic based on FDG-PET/CT. Thus, some of the cases classified as correctly staged for ECR by FDG-PET/CT, may have been erroneously classified. This limitation shared by most published studies including the studies on cervical cancer recurrence, is however hard to circumvent, as it seems unethical to perform biopsies of all suspected metastatic lesions in patients due to risk of complications. Furthermore, frequent FDG PET/CT follow-up scans is both very expensive and implies unwanted radiation exposure for the patients.
As both LNM and endometrial cancer recurrence studies exhibit inter study heterogeneity, the SROC curve should be asymmetric ( Supplementary Fig.1 for both symmetric and asymmetric SROCs). Since all possible curves with the same true odds ratio and different degrees of heterogeneity would pass through the same point on the anti-diagonal, the heterogeneity does not affect the Q* estimate, but rather the shape of the curve and its standard errors. Walter et al. (30) notes that the AUC standard errors calculated under the homogeneity assumption provide a good approximation for heterogeneous studies. The approximation may be poor for extremely high DOR values (higher than 20), as is the case in both meta-analyses presented here (37.5 and 171.7
for LNM and recurrence, respectively). However, the bias in the homogeneity-based standard errors is mostly positive, and hence conservative, i.e. can be overestimated, but rarely underestimated. The supplementary Fig. 1 illustrates that the confidence intervals of the asymmetric SROC are much narrower compared to those of the symmetric SROC, while the difference between the AUC estimates is negligible.
This meta-analysis has several limitations. First, positive result publication bias is a major concern, since non-significant or unfavourable study results tend to be discarded. However, we evaluated publication bias in our meta-analysis using funnel plot asymmetry, finding the funnel plots to be symmetric for both sensitivity and specificity pooling, implying no large bias in our study. Second, the current meta-analysis did not include region by region or node by node evaluation since this was not reported in most studies; however, this could have provided additional information. Third, not all included studies had a prospective study design. Fourth, the gold standard for confirmation of LNM or ECR, being histopathological examination from biopsies, was not obtained from all the lesions reported in the studies. However, clinical followup data and results from renewed diagnostic imaging were recorded and clinically putative lymph nodes metastases or endometrial cancer recurrence was used as gold standard when histologic confirmation was missing.
CONCLUSION
Overall FDG-PET/CT demonstrated high diagnostic performance in identifying lymph node metastases preoperatively and in detecting recurrence after endometrial carcinoma surgery with curative intent. Larger prospective studies are needed to validate this high diagnostic performance of FDG-PET/CT in endometrial cancer and further assess patient subgroups with particular clinical benefit from applying this advanced imaging procedure.
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